CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Supernus Pharmaceuticals Inc  (SUPN)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 
 


Supernus Pharmaceuticals Inc

SUPN's Fundamental analysis



You need to upgrade your Flash Player

Looking into Supernus Pharmaceuticals Inc growth rates, revenue grew by 46.88 % in II. Quarter 2017 from the same quarter a year ago. Ranking at No. 446

Supernus Pharmaceuticals Inc's averge rate of year on year quarterly revenue increase, is at1313.01 %.

Major Pharmaceutical Preparations industry recorded growth of revenues by 11.89 %

Supernus Pharmaceuticals Inc's net income grew by 69.43 % in II. Quarter 2017 year on year, below company average,

More on SUPN's Growth




Supernus Pharmaceuticals Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Supernus Pharmaceuticals Inc PEG ratio is at 0.07 , above Major Pharmaceutical Preparations industry PEG average of -3.28.
Company
20
PE TTM    
Industry
44.24
PE TTM    
Company's Price to Sales ratio is at 8.22.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 14.38.

Supernus Pharmaceuticals Inc Price to Book Ratio is at 9.05 higher than Indusry Avg. of 4.11, and higher than S&P 500 Avg. of 3.29

More on SUPN's Valuation





 Market Capitalization (Millions $) 2,076
 Shares Outstanding (Millions) 53
 Employees -
 Revenues (TTM) (Millions $) 253
 Net Income (TTM) (Millions $) 104
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) -26
You need to upgrade your Flash Player
 Total Debt (Millions $) 1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover Ratio (TTM) 6.02
 Tangible Book Value (Per Share $) 3.77

Profitability

Supernus Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2017 to 34.38 % from 29.16 % in I. Quarter.

Supernus Pharmaceuticals Inc net profit margin of 22.9 % is currently ranking no. 12 in Major Pharmaceutical Preparations industry, ranking no. 42 in Healthcare sector and number 606 in S&P 500.

More on SUPN's Key Ratios
You need to upgrade your Flash Player

You need to upgrade your Flash Player
  Ratio
  Working Capital Ratio (MRQ) 1.94
  Total Debt to Equity (MRQ) 0.01
  Tangible Leverage Ratio (MRQ) 0.58
  Asset Turnover Ratio (TTM) 0.8
  Inventory Turnover Ratio (TTM) 0.8
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CSL's Profile

Stock Price

CSL's Financials

CSL's Expectations

Business Description

Fundamentals

Charts & Quotes

CSL's News

Suppliers

CSL's Competitors

Customers & Markets

Economic Indicators

CSL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com